Keywords
Vaccination
Children
Abstract
Introduction. There are controversies over the long-term persistence of post vaccination immunity to hepatitis B and the need for booster doses of the vaccine. The aim of this study was to verify antibody levels of antibody against hepatitis B virus surface antigen (anti-HBs) in children aged 1 to 15 years who received vaccination against hepatitis B in the central province of Iran, Semnan. Materials and methods. We performed a seroepidemiological survey (n = 210) of anti-HBs in 2011 in the central province of Iran, Semnan using enzyme-linked immunosorbent assay (ELISA). The levels of anti-HBs inf. 10 mIU/mL were considered to be negative and samples showing an anti-HBs titer ? 10 mIU/mL was considered protective. Results. Protective antibody levels were detected in 88% of the children less than 5 year after vaccination, decreased to 78% between 5 to 10 years after vaccination, and further declined to 74% in 10 years after vaccination, respectively. Conclusion. The vaccination program has been proven effective in Semnan and immunological protection against hepatitis B infection was found in the majority of children even more than 10 years after being vaccinated.References
Kwon SY, Lee CH. Epidemiology and prevention of hepatitis B virus infection. Korean J Hepatol. 2011;17:87–95.
Poorolajal J, Mahmoodi M, Majdzadeh R, et al. Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis. Vaccine. 2010;28:623–631.
Fagundes GD, Tabalipa FdO, Silva Jd. Antibody levels in children after 10 years of vaccination against hepatitis B: a brazilian community-based study. Revista da Sociedade Brasileira de Medicina Tropical. 2012;45:260–262.
Alavian SM, Hajarizadeh B, Ahmadzad-Asl M, et al. Hepatitis B Virus infection in Iran: A systematic review. Hepat Mon. 2008;8:281–294.
Hollinger FB, Liang TJ. Fields Virology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001. Hepatitis B virus; pp. 2971–3036.
Mahoney FJ, Kane M. Hepatitis B vaccine. Vaccines. 1999;3:158–182.
Boxall EH, Sira JA, El-Shuhkri N, et al. Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low. J Infect Dis. 2004;190:1264–1269.
Alexandre KVF, Martins RMB, Souza MMd, et al. Brazilian hepatitis B vaccine: a six-year follow-up in adolescents. Memórias do Instituto Oswaldo Cruz. 2012;107:1060–1063.
Huang LM, Chiang BL, Lee CY, et al. Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Hepatology. 1999;29:954–959.
Wu JS, Hwang L-Y, Goodman KJ, et al. Hepatitis B vaccination in high-risk infants: 10-year follow-up. J Infect Dis. 1999;179:1319–1325.
FitzSimons D, François G, Hall A, et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine. 2005;23:4158–4166.
McMahon BJ, Bruden DL, Petersen KM, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med. 2005;142:333–341.
Gilca V, Serres G, Boulianne N, et al. Antibody persistence and the effect of a booster dose given 5, 10 or 15 years after vaccinating preadolescents with a recombinant hepatitis B vaccine. Vaccine. 2013;31:448–451.
Whittle H, Jaffar S, Wansbrough M, et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ. 2002;325:569–569.
Nakao K, Hamasaki K, Wakihama N, et al. Analysis of anti-HBs levels in healthcare workers over 10 years following booster vaccination for hepatitis B virus. Vaccine. 2003;21:3789–3794.
But DY-K, Lai C-L, Lim W-L, et al. Twenty-two years follow- up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine. 2008;26:6587–6591.
AlFaleh F, AlShehri S, AlAnsari S, et al. Long-term protection of hepatitis B vaccine 18 years after vaccination. J Infect. 2008;57:404–409.
Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007;16:403–403.
Jafarzadeh A, Sajjadi S. Persistence of anti-HBs antibodies in healthy Iranian children vaccinated with recombinant hepatitis B vaccine and response to a booster dose. Acta Med Iranica. 2005;43:79–84.
Jafarzadeh A, Montazerifar SJ. Persistence of anti-HBs antibody and immunological memory in children vaccinated with hepatitis B vaccine at birth. J Ayub Med Coll Abbottabad. 2006;18:4–9.
Aghakhani A, Banifazl M, Izadi N, et al. Persistence of antibody to hepatitis B surface antigen among vaccinated children in a low hepatitis B virus endemic area. World J Pediatr. 2011;7:358–360.